Cross-Sector entity
U.S. Food and Drug Administration is most often covered alongside Philip Morris International, which appears in 4 of these 16 stories. The 137-day window averages about 0.8 stories each week. The busiest single day carried 4. market-trends accounts for 4 of the 16 tracked stories, while 6 other categories carry the remainder.
16 verified stories tracked
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 75 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
U.S. Food and Drug Administration is most often covered alongside Philip Morris International, which appears in 4 of these 16 stories. The 137-day window averages about 0.8 stories each week. The busiest single day carried 4. market-trends accounts for 4 of the 16 tracked stories, while 6 other categories carry the remainder. Each carries 4.4 original sources on average. Negative sentiment appears in 6% of the tracked stories. This profile follows 16 Cross-Sector stories mentioning U.S. Food and Drug Administration across the period from February 18, 2026 to July 4, 2026.
Computed from the 16 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering U.S. Food and Drug Administration. Shared-story counts are live from our verified record — not editorial picks.
Potential EU Launch
Target window for commercial availability of iopofosine I 131 in Europe.
Target Commercialization
Anticipated EU launch for iopofosine I 131 treatment of WM.
EMA Submission
Planned filing of Conditional Marketing Authorization for iopofosine I 131.
CLR 125 Data
Expected early data readout from Phase 1b study in triple-negative breast cancer.
JPM Q1 Earnings Report
JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny.
FDA Orforglipron Decision
Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss.
Phase III Initiation
First patient dosed at Peking Union Medical College Hospital in China.
Earnings Release
Both companies report Q4 and FY 2025 financial results and business highlights.
Financial Results
Company reports 2025 results and provides corporate update.
Annual Results Announcement
CEO James Caruso provides corporate updates and confirms regulatory timelines.
FDA Partial Hold
FDA notifies PepGen of partial clinical hold on Freedom2 trial.
Expedited Pathway Formalized
FDA announces the formal implementation of quicker paths for gene therapy via surrogate endpoints.
Regulatory Designations
FDA grants Fast Track and NMPA grants Breakthrough Therapy status.
Regulatory Designations
HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations.
Trial Expansion
Continued enrollment across global multicenter sites for the 24-week study.
Fiscal Year End
Cellectar completes a year of pipeline advancement and platform validation.
Phase II Data Publication
Results showing efficacy without hormonal side effects published in The Lancet.
START Pilot Launch
FDA initiates a pilot program for Support for clinical Trials Advancing Rare disease Therapeutics.
CBER Reorganization
The Office of Tissues and Advanced Therapies is elevated to a 'Super Office' to handle CGT volume.
Zepbound Approval
FDA expands tirzepatide approval to include chronic weight management.
PM shares rose 1.5% in after‑hours trading on the back of FDA authorization allowing ZYN to market 10 flavors with reduced‑exposure claims, strengthening the company’s smoke‑free pivot and widening its competitive moat.
Philip Morris’s ZYN secured the first FDA modified risk orders for a nicotine pouch, authorizing reduced‑exposure marketing for 10 flavors. The decision sets a regulatory benchmark for oral nicotine products.
Philip Morris’s ZYN secured FDA authorization to market ten flavors as reduced‑exposure products. Retailers may see a surge in demand from adult smokers switching from cigarettes, shifting shelf space and consumer behavior.
The FDA authorized modified risk orders for ten ZYN nicotine pouch flavors, permitting claims that they reduce exposure to harmful chemicals. Health policymakers face new questions on harm reduction, youth appeal, and postmarket proof.
Source: Tajsabreen Ahamed (us) · Rttnews
The 2025 National Youth Tobacco Survey reports a record low but persistent 5.2% youth e-cig use, intensifying American Lung Association demands for FDA to reverse its flavored vape authorizations. This regulatory reversal could spawn new administrative law challenges and test the scope of FDA’s tobacco authority, especially given the nearly 90% flavor preference among underage users. Legal experts weigh the viability of forced authorization revocations against public health considerations.
Source: wgxa.tv · nbcmontana.com
Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.
Source: Woonsocketcall · Laotian Times
Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies.
Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
Source: Adria Cimino (us) · fool.com
Texas Governor Greg Abbott has launched a formal investigation into the safety and security of medical devices manufactured in China and used within the state's healthcare system. The move signals a growing trend of state-level scrutiny over international medical supply chains and potential vulnerabilities in critical healthcare infrastructure.
OmniAb and PepGen reported full-year 2025 results, highlighting a divergence between platform-based stability and clinical-stage volatility. While OmniAb expanded its royalty-bearing portfolio, PepGen faced a significant setback with a partial FDA clinical hold on its Freedom2 trial.
Source: pharmiweb.com · pharmiweb.com
Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform.
Cellectar Biosciences has announced its 2025 year-end results, highlighting a strategic shift toward European commercialization for its lead radiotherapeutic, iopofosine I 131. The company remains on track for a Q3 2026 regulatory submission to the EMA, while simultaneously advancing its Phase 1b study for CLR 125 in triple-negative breast cancer.
Source: The Manila Times · Benzinga
The U.S. Food and Drug Administration is introducing a landmark performance-based bonus system for staff members who complete drug application reviews ahead of schedule. This shift toward private-sector incentive models aims to clear regulatory backlogs and accelerate patient access to new therapies.
The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.
The U.S. Food and Drug Administration is moving to eliminate the long-standing requirement for two pivotal clinical trials for new drug approvals. This regulatory shift aims to significantly reduce the time and cost of drug development, prioritizing faster patient access to innovative therapies.
Source: dailybulletin.com · baltimoresun.com
